Skeletal Toxicity of Thiazolidinediones

Letters1 April 2008Skeletal Toxicity of ThiazolidinedionesAndrew B. Grey, MDAndrew B. Grey, MDFrom the University of Auckland, Auckland 1142, New Zealand.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-148-7-200804010-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Patients with type 2 diabetes mellitus are at increased risk for fracture compared with their euglycemic peers (1). In their review of the comparative safety of oral therapies for type 2 diabetes mellitus, Bolen and colleagues (2) refer to evidence from the ADOPT (A Diabetes Outcome Progression Trial) study that fracture incidence increased by about 2-fold in women with type 2 diabetes mellitus taking rosiglitazone compared with those taking either glyburide or metformin. An increased fracture risk in women has also been reported from a preliminary analysis of an ongoing rosiglitazone trial (3) and from a pooled ...References1. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008;19:129-37. CrossrefMedlineGoogle Scholar2. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147:386-99. [PMID: 17638715] LinkGoogle Scholar3. Letter from Alexander R. Corbitz (GlaxoSmithKline) to health care providers, February 2007. Re: Clinical Trial Observation of an Increased Incidence of Fractures in Female Patients Who Received Long-Term Treatment with Avandia® (rosiglitazone maleate) Tablets for Type 2 Diabetes Mellitus. Accessed at www.fda.gov/medwatch/safety/2007/Avandia_GSK_Ltr.pdf on 13 February 2008. Google Scholar4. Letter from Robert Spanheimer, MD (Taneka Pharmaceuticals North America), to health care providers, March 2007. Re: Observation of an Increased Incidence of Fractures in Female Patients Who Received Long-Term Treatment with ACTOS® (pioglitazone HCl) Tablets for Type 2 Diabetes Mellitus. Accessed at www.fda.gov/medwatch/safety/2007/Actosmar0807.pdf on 13 February 2008. Google Scholar5. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92:1305-10. [PMID: 17264176] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From the University of Auckland, Auckland 1142, New Zealand.Disclosures: Dr. Grey received consulting fees from GlaxoSmithKline. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSystematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus Shari Bolen , Leonard Feldman , Jason Vassy , Lisa Wilson , Hsin-Chieh Yeh , Spyridon Marinopoulos , Crystal Wiley , Elizabeth Selvin , Renee Wilson , Eric B. Bass , and Frederick L. Brancati Metrics Cited ByHaemodialysis-induced hypoglycaemia and glycaemic disarraysAdverse skeletal effects of drugs - beyond GlucocorticoidsDiabetic Kidney Disease: A Report From an ADA Consensus ConferenceDiabetic Kidney Disease: A Report From an ADA Consensus ConferenceNew-onset diabetes after transplantation: Risk factors and clinical impactDiabetes melito, tiazolidinedionas e fraturas: uma história inacabadaStimulation of glucose uptake by triterpenoids from Weigela subsessilisGenistein-Derivatives from Tetracera scandens Stimulate Glucose-Uptake in L6 MyotubesCurrent awareness: Pharmacoepidemiology and drug safety 1 April 2008Volume 148, Issue 7Page: 563KeywordsConflicts of interestHypoglycemicsMesenchymal stem cellsProspective studiesRisk managementSafetySafety studiesToxicityType 2 diabetes ePublished: 1 April 2008 Issue Published: 1 April 2008 CopyrightCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...